Central to this new wave of research is the enhancement of the Flow Cytometry Shared Resource core facility, spearheaded by Michael T. Berton, PhD. This facility has been a backbone for cancer researchers across South Texas, providing state-of-the-art spectral flow cytometry capabilities for single-cell analysis and purification. The new grant will facilitate upgrades that enable imaging flow cytometry, a technique that transcends traditional fluorescence-based sorting by integrating physical and spatial attributes through high-resolution, real-time imaging. This technological leap allows detailed examination of cell morphology and biomarker distribution at a single-cell level, which can reveal novel cancer cell phenotypes and behaviors vital for understanding tumor heterogeneity and treatment resistance.

Ewing sarcoma, a rare but aggressive pediatric cancer, remains notoriously difficult to treat due to the elusive nature of its key oncogenic driver protein, EWS::FLI1, which lacks a stable conformation suitable for conventional drug binding. David Libich, PhD, is leading groundbreaking research to overcome this challenge by decoding the protein-protein interactions of EWS::FLI1 at atomic-resolution using advanced imaging techniques such as cryo-electron microscopy and nuclear magnetic resonance spectroscopy. Coupling these structural biology insights with sophisticated artificial intelligence modeling, the project aims to design synthetic proteins that can specifically latch onto the EWS::FLI1 fusion oncoprotein. These engineered molecules act as precision inhibitors, either blocking the protein’s oncogenic activity or marking it for degradation. If successful, this approach could revolutionize targeted therapy for Ewing sarcoma by offering a molecularly precise, less toxic alternative to conventional chemotherapeutics.

In parallel, Arkajyoti Roy, PhD, focuses on harnessing artificial intelligence to democratize access to high-quality radiation therapy, a cornerstone cancer treatment modality. Radiation therapy requires meticulous delineation of tumor boundaries and adjacent critical organs on CT imaging to maximize tumor dose while sparing healthy tissue. This segmentation step is labor-intensive and suffers from variability, particularly in under-resourced rural and underserved clinics. Roy’s project aims to build AI models trained on diverse clinical datasets that not only predict anatomical contours but also quantify the uncertainty of these predictions. Incorporating uncertainty-aware AI into radiation planning algorithms promises treatment plans with built-in safety margins, ensuring effective and equitable care even in settings lacking specialized expertise. This innovation could significantly reduce disparities in cancer treatment quality and outcomes across geographical and socioeconomic boundaries.

Addressing the rising incidence of obesity-linked endometrial cancer, Maria Gonzalez Porras, PhD, investigates novel nanoparticle-based therapies targeting tumor microenvironmental crosstalk. Obesity exacerbates endometrial carcinogenesis by promoting migration of adipose-derived cells to the uterus, exacerbating tumor growth via secreted proliferative proteins and enhanced crosstalk mediated by specific surface proteins on both fat and cancer cells. Employing engineered nanoparticles loaded with genetic payloads, this therapeutic approach selectively silences these pathogenic mediators in situ within tumor-supporting cells. By delivering genetic instructions to deactivate tumor-promoting proteins, the nanomedicine aims to disrupt the obesity-fueled tumor microenvironment while limiting systemic exposure and adverse effects. This precision therapy has the potential to preserve fertility and reduce side effects compared to conventional invasive therapies, offering a promising new horizon for personalized medicine in this vulnerable patient population.

These multifaceted research initiatives epitomize the collaborative spirit essential to transforming cancer care. Patrick Sung, DPhil, director of the Greehey Children’s Cancer Research Institute, emphasizes that groundbreaking cancer research thrives at the nexus of curiosity, interdisciplinary collaboration, and compassionate dedication. The institute itself stands as a beacon, devoted exclusively to pediatric cancer research and innovation. Its unique focus on genomic instability, RNA biology, and novel drug development drives efforts to convert compelling laboratory findings into tangible cures for children facing cancer.

The CPRIT funding thus catalyzes a comprehensive approach, merging cutting-edge molecular technologies, AI-driven clinical tools, and nanomedicine to address heterogeneous cancer challenges. The enhanced Flow Cytometry Shared Resource facility empowers researchers with unprecedented cellular phenotyping capabilities, laying groundwork for the discovery of novel biomarkers and therapeutic targets. Structural elucidation of the elusive EWS::FLI1 fusion protein opens avenues for rational drug design that might redefine targeted therapy for sarcomas. Artificial intelligence models promise to standardize and optimize radiation oncology workflows, improving outcomes particularly in underserved populations. Nanoparticle vehicles for precise gene silencing herald a new generation of safer, fertility-conscious cancer therapeutics.

Ultimately, this constellation of efforts by UTSA, UT Health San Antonio, and affiliated researchers propels the frontiers of cancer biology and treatment innovation. By integrating multidisciplinary expertise spanning molecular biology, computational sciences, engineering, and clinical oncology, these programs illuminate pathways to more effective, equitable, and personalized cancer care. The investments from CPRIT not only fuel vital scientific discovery but also exemplify a purposeful commitment to improving the health and lives of cancer patients across South Texas and beyond, forging links between pioneering research and real-world impact.

As the Mays Cancer Center at UT Health San Antonio—one of the four National Cancer Institute-designated Cancer Centers in Texas—continues to expand its research footprint, its partnership with MD Anderson Cancer Center enhances access to the nation’s most advanced cancer therapies locally. This symbiotic relationship accelerates knowledge exchange and clinical innovation, strengthening cancer prevention and treatment paradigms. Similarly, the Greehey Children’s Cancer Research Institute’s unparalleled dedication to childhood cancers ensures that emerging pediatric therapies are developed with rigor and compassion.

The technological advancements in flow cytometry, atomic-level structural biology, AI-powered radiation oncology, and nanoparticle therapeutic delivery underscore a paradigm shift in precision oncology. Such multidisciplinary convergence enhances our ability to decrypt cancer biology intricacies and translates this understanding into actionable clinical strategies. With continued investment and visionary leadership, these scientific endeavors promise to reshape cancer prevention, diagnosis, and therapy, ultimately heralding a future where cancer morbidity and mortality are substantially diminished.

For the scientific community and public alike, UT Health San Antonio’s recent awardees exemplify how leveraging advanced technologies and cross-sector collaboration can generate impactful cancer research that fuels hope and innovation. These developments spotlight the critical role academic health centers play in transforming research breakthroughs from the bench to bedside, delivering tangible benefits to patients throughout South Texas and beyond. As the frontier of cancer research advances, these programs will serve as a model of translating cutting-edge science into life-saving interventions with lasting societal benefits.

Subject of Research: Cancer research including flow cytometry technology advancement, targeting Ewing sarcoma protein interactions, AI-driven radiation therapy, and nanoparticle-based therapies for obesity-linked endometrial cancer.

Article Title: UT Health San Antonio Advances Cancer Research with $2.7 Million CPRIT Grant Boosting Flow Cytometry, AI, and Targeted Therapies

News Publication Date: June 2, 2026

Web References:

• https://www.uthscsa.edu/
• https://cprit.texas.gov/
• https://cancer.uthscsa.edu/
• https://uthscsa.edu/medicine/
• https://gccri.uthscsa.edu/
• https://wp.uthscsa.edu/flow-cytometry/
• https://business.utsa.edu/
• https://klesse.utsa.edu/
• https://cancer.uthscsa.edu/gccri

Keywords

Cancer research, Flow cytometry, Ewing sarcoma, Artificial intelligence, Radiation therapy, Nanoparticles, Endometrial cancer, Obesity, Pediatric cancer, Structural biology, Precision oncology, Molecular therapeutics

Developed through a collaborative effort between the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and teams at the University of California, San Francisco as well as the Helen Diller Family Comprehensive Cancer Center, CIPHER-seq represents a significant step forward in immune profiling. Unlike traditional approaches that primarily focus on RNA sequencing, which captures the “blueprint” of cellular activity, this method integrates multiple layers of biological information by also quantifying proteins both on and within the cell. This layered analysis provides a clearer, more dependable window into cellular function, tracing the direct molecular players responsible for immune responses, including cytokines, the potent signaling proteins critical to immune communication and regulation.

Single-cell RNA sequencing has vastly expanded the horizon of biomedical research by allowing high-throughput characterization of gene expression across thousands of individual cells. However, RNA transcripts alone can provide an incomplete and sometimes misleading portrayal of cellular states, as they represent instructions that do not always correlate with final protein output. This discrepancy is especially pronounced for cytokines—key mediators that dictate immune cell behavior, guide inflammatory responses, and influence tumor dynamics. RNA levels fluctuate rapidly and are transient, while proteins accumulate more slowly and persist longer, creating a temporal disconnect that RNA sequencing alone cannot resolve. Hence, understanding immune responses necessitates an integrative approach combining both RNA and protein data to capture the full biological narrative.

CIPHER-seq addresses this complexity by gently preserving immune cells during processing, thus minimizing artificial stress responses that have confounded earlier methods. Standard preparation techniques can induce mitochondrial stress and other cellular perturbations, thereby polluting data with artifacts that mask authentic biological signals. The gentle preservation employed in CIPHER-seq maintains cells closer to their natural physiological state, ensuring that measurements reflect true cellular function rather than experimental distortion. This refinement is crucial for accurately mapping the nuanced processes by which immune cells activate, communicate, and regulate their environments, especially within the challenging context of cancer and inflammation.

Technically, CIPHER-seq captures a comprehensive immunological snapshot from a single cell by simultaneously profiling the entire transcriptome along with intracellular and surface protein markers, including the cytokines sequestered within cells before secretion. The methodology integrates advanced sequencing protocols with protein detection reagents, enabling the simultaneous measurement of thousands of RNA molecules alongside the phenotypic markers and signaling proteins that define the cell’s current status. This multimodal profiling unveils the precise molecular choreography that governs immune activity, facilitating a detailed reconstruction of how cells respond to stimuli and enact immune functions at the molecular level.

To validate the capabilities of this platform, researchers conducted activation assays whereby immune cells were stimulated and tracked over time. CIPHER-seq successfully detected dynamic increases in the production of critical cytokines such as interferon-gamma and tumor necrosis factor—both central players in modulating immune defense and tumor suppression. Through sophisticated computational algorithms that arrange cells along temporal trajectories of activation, the study observed that RNA levels surged first as cells “planned” their response, followed by a subsequent, modestly delayed rise in protein expression, representing the “execution” phase of immune activity. This sequential timing underscores the value of analyzing both RNA and protein simultaneously to unravel the true dynamics of immune responses.

The ability to monitor cytokines at both the transcriptional and protein levels enhances the granularity with which scientists can understand the mechanisms by which immune cells decide to attack cancer cells, ignore them, or paradoxically support tumor growth through chronic inflammation or immune suppression. By moving beyond static single-layer snapshots to continuous, multimodal timelines, CIPHER-seq empowers researchers to uncover hidden regulatory steps, identify novel biomarkers, and elucidate resistance pathways that have heretofore remained obscured in cancer immunology. These insights have far-reaching implications for advancing immunotherapy—tailoring treatments that are not only more effective but also personalized to a patient’s unique immune landscape.

Justin Taylor, M.D., Sylvester physician-scientist and co-senior author of the study, emphasizes that proteins reveal the actual functional endpoints of immune signaling that RNA alone cannot specify. “RNA gives us clues about where a cell is headed,” Dr. Taylor explains, “but proteins show us where it actually arrives. This clearer picture could significantly refine how immunotherapies are designed and how clinicians anticipate treatment outcomes.” This transformative perspective reconceptualizes immunology research, prioritizing integrated molecular datasets that mirror biological reality rather than relying on partial, indirect proxies of cellular activity.

The implications of CIPHER-seq extend beyond cancer to other immune-mediated diseases characterized by aberrant cytokine activity and immune dysfunction. Chronic inflammatory disorders, autoimmune diseases, and infections could all benefit from this technology’s ability to decode immune cell behavior with greater accuracy and precision. By providing a robust, low-artifact platform that delineates the timing and magnitude of cytokine production and signaling events across heterogeneous immune cell populations, scientists can develop targeted therapeutic strategies that modulate immune responses more effectively and safely.

Moreover, the computational framework accompanying CIPHER-seq analysis leverages advanced bioinformatics to correlate complex data streams from RNA and protein channels, mapping immune cell populations onto activation trajectories and functional states with remarkable resolution. This approach empowers researchers to dissect intercellular heterogeneity, pinpoint subtle regulatory nodes, and predict cellular fates in response to tumor microenvironments or therapeutic interventions. The fusion of experimental and computational innovations embodied by CIPHER-seq marks a milestone for systems immunology, setting new standards for accuracy and depth in single-cell profiling technologies.

Looking ahead, integration of CIPHER-seq with other emerging single-cell technologies, such as spatial transcriptomics and epigenetic profiling, could further enhance our ability to chart immune responses in situ within tissue architectures. Such multimodal profiling at unprecedented scales holds the promise to unveil the spatial and temporal regulatory networks that drive immune evasion, inflammation resolution, and therapeutic resistance. As researchers continue to refine and expand this technology, CIPHER-seq is poised to become an indispensable tool in the arsenal for cancer immunotherapy research and beyond, bridging fundamental biology and clinical application in the quest to decipher and harness the immune system.

In summary, the advent of CIPHER-seq constitutes a transformative advance in single-cell immunology by capturing the dual biochemical narratives of RNA and protein within the same immune cells. This multimodal platform transcends the limitations of prior methodologies by reducing artificial cell stress and revealing the precise sequence of cytokine gene and protein expression during immune activation. Providing an integrative and dynamic portrait of immune cell behavior, CIPHER-seq lays the groundwork for improved immunotherapeutic strategies and more accurate clinical predictions in cancer and other immune-related diseases. The study’s publication in the April 8, 2026 issue of Scientific Reports signals a new era in combining molecular granularity with temporal resolution, fostering a deeper understanding of how immune responses genuinely unfold one cell at a time.

Subject of Research: Immune cell behavior and cytokine signaling profiling using multimodal single-cell sequencing technology

Article Title: CIPHER-seq enables intracellular multimodal profiling of cytokine responses in single immune cells

News Publication Date: April 8, 2026

Web References:
http://dx.doi.org/10.1038/s41598-026-44946-y

Image Credits: Photo by Sylvester Cancer

Keywords: Cancer immunotherapy, Cytokines, Cancer genomics, Genome sequencing, RNA sequencing, Single cell sequencing, Immune cells, Cancer immunology, Immunotherapy

Multiple myeloma, a hematological malignancy characterized by the abnormal proliferation of plasma cells, presents unique challenges, especially in its relapsed and refractory forms. Patients typically undergo a series of therapeutic regimens, often exposing them to a variety of drugs across different classes. As treatment options dwindle and disease progression continues, the need for innovative therapies becomes paramount. This urgency drives research into CAR T-cell therapies—customized immune cells trained to target and eliminate cancer cells.

Ciltacabtagene Autoleucel and Idecabtagene Vicleucel represent cutting-edge advancements in CAR T-cell technology. These treatments harness the patient’s immune system to induce a targeted attack on malignant plasma cells, bypassing many limitations of traditional chemotherapeutic agents. Previous studies have shown promising efficacy of both therapies; nevertheless, a direct comparison using updated methodologies provides renewed hope for clinicians striving to tailor interventions that optimize patient outcomes.

The study utilized a matching-adjusted indirect comparison (MAIC) methodology to assess the relative efficacy of the two therapies. This technique allows researchers to account for differences in baseline characteristics between previously conducted trials, ensuring that comparisons are valid and meaningful. The implementation of MAIC is particularly pertinent in oncology, where heterogeneity among patient populations can obfuscate results when direct head-to-head trials are infeasible. By bridging gaps between existing data, the findings hold immense potential to inform clinical decision-making.

Understanding the nuances of how these CAR T-cell therapies function is imperative for interpreting the study results. Both Ciltacabtagene Autoleucel and Idecabtagene Vicleucel utilize engineered T-cells to target B-cell maturation antigen (BCMA), a protein frequently overexpressed in multiple myeloma cells. Upon infusion, these modified T-cells recognize and bind to BCMA, initiating a robust immune response that leads to myeloma cell lysis. Moreover, variations in the genetic constructs of these therapies may lead to differences in efficacy and safety profiles, further complicating clinical choices.

Evaluating the outcomes based on efficacy endpoints such as overall response rate (ORR) and progression-free survival (PFS) illuminates the potential differences between these two groundbreaking treatments. The study’s findings reveal that while both therapies confer notable ORR in challenging patient populations, subtle differences in PFS may impact the therapeutic landscapes. Understanding these distinctions allows clinicians to make strategic decisions about treatment plans tailored to individual patient characteristics.

Beyond efficacy, the safety profiles of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel are crucial to consider, particularly given the potential for adverse events. Adverse effects associated with CAR T-cell therapy can include cytokine release syndrome (CRS), neurological toxicities, and hematologic toxicities, all of which require careful monitoring post-infusion. This study aims to elucidate these risks and provide a comprehensive understanding of the benefit-risk relationship, which is pivotal for informed patient conversations and shared decision-making.

The role of clinician experience and institutional capabilities can significantly shape patient outcomes with CAR T-cell therapy. This consideration becomes essential when interpreting study results, as healthcare providers must navigate logistical challenges and institutional protocols unique to the administration of these advanced therapies. Ensuring appropriate patient selection and optimizing supportive care measures are also avenues to enhance outcomes in the real-world setting.

Rising costs and accessibility issues also pose challenges within the realm of advanced myeloma therapies. Understanding the economic implications of treatment choices necessitates thorough evaluation, including a review of healthcare utilization and cost-effectiveness. Insights gained from the study serve to guide not only clinical practices but also policy recommendations that can enhance accessibility for all patients in need of innovative treatment options.

As the study unfolds, the broader implications of these findings echo throughout the hematology community. Clinicians, researchers, and patients alike stand to benefit from the insights garnered from this comparative analysis. Adoption of evidence-based practices based on robust data can transform clinical outcomes and improve the quality of life for those grappling with this complex malignancy.

Ultimately, as therapeutic options evolve, continuous research remains crucial for advancing treatment frontiers in multiple myeloma. Studies like the one led by Lopez-Muñoz et al. lay the groundwork for assuring that patients receive optimized therapies tailored to their unique clinical scenarios. Such efforts not only enrich the scientific understanding of these therapies but also advocate for equitable access to groundbreaking treatments for all patients.

In summary, the findings presented in this updated comparison mark a significant step forward in the armamentarium against relapsed and refractory multiple myeloma. As this research continues to unfold, the medical community must remain vigilant in translating insights into actionable strategies that empower patients and improve survival outcomes. The intersection of precision medicine and advanced cellular therapies heralds a new era of hope for those affected by this challenging disease.

Subject of Research: Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma

Article Title: Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2–4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison

Article References: Lopez-Muñoz, N., Bar, N., Diels, J. et al. Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2–4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison. Adv Ther (2026). https://doi.org/10.1007/s12325-025-03479-y

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12325-025-03479-y

Keywords: CAR T-cell therapy, multiple myeloma, Ciltacabtagene Autoleucel, Idecabtagene Vicleucel, efficacy, safety profiles, matching-adjusted indirect comparison, treatment outcomes.

Patient-derived organoids are generated from individual patient tumors, allowing them to closely replicate the unique genetic and molecular landscape of a person’s cancer. This characteristic makes them invaluable for personalized medicine, where treatments can be tailored based on the specific tumor biology of a patient. The organoid technology holds profound implications for understanding tumor behaviors, drug responses, and mechanisms of resistance in TOC. Researchers are excited about the potential to use these models to explore the nuances of why some patients respond well to therapy while others do not.

The study conducted by the researchers emphasizes the role of organoids in bridging the gap between preclinical models and clinical outcomes. Traditional models have often fallen short in their ability to predict patient responses, but organoids offer a more accurate representation of human cancer. This research captures an essential paradigm shift where the individual patient’s tumor is not merely a source of cells but is transformed into a living model that can be studied to extract crucial information for advancing treatment protocols.

In their meticulous approach, the team isolated viable cancer cells from patients diagnosed with tubo-ovarian carcinoma, subsequently culturing them to form organoids. These organoids retained the histopathological characteristics of the original tumors, making them an ideal platform for in-depth analyses. Furthermore, the authors highlight the diversity of TOC, with variations in histological subtypes that have different biological behaviors and responses to treatment. The organoid culture allows for high-throughput testing of various therapeutic agents, providing insights into which combinations may be most effective for specific subtypes of the disease.

One of the most exciting aspects of this research is the potential for robotic automation in drug screening processes. By utilizing organoids, researchers can employ robotic systems to rapidly expose multiple organoid variants to numerous pharmacological agents. This automation could expedite the identification of effective treatment regimens while minimizing human error. Furthermore, the data gleaned from organoid studies could directly inform clinical trials, enhancing their design and execution.

Another significant finding from Alves-Vale et al.’s research involves the importance of microenvironmental cues in shaping tumor behavior. The organoids retain the structural and biochemical factors of the tumor microenvironment, which play critical roles in cancer progression and metabolism. Understanding these interactions will offer new avenues for therapeutic interventions, as modifying the microenvironment could shift the dynamics of tumor growth and response to treatment.

The study also explores the genetic underpinnings of tubo-ovarian carcinoma through the organoid platform. By sequencing the DNA and RNA from the organoids, researchers can identify mutations and expression patterns that could elucidate the underlying mechanisms of the disease. This molecular characterization is vital for developing targeted therapies, as it allows researchers to pinpoint specific pathways that may be aberrantly activated in patient tumors.

One of the challenges faced in tumor biology is the intratumoral heterogeneity observed in cancers como tubo-ovarian carcinoma. This variability often contributes to the failure of therapies, as a treatment may effectively target one cell population while leaving others untouched. Organoids present an opportunity to study this heterogeneity in a controlled setting, enabling researchers to better understand how different cellular populations respond to treatment and what strategies could be employed to target them effectively.

Additionally, Alves-Vale et al. address the potential for organoids to assist in identifying biomarkers for early detection and prognosis of tubo-ovarian carcinoma. The ability to derive organoids from early-stage tumors raises the possibility of screening interventions that could improve patient outcomes by allowing for earlier treatment initiation. As the research continues to unfold, the identification of reliable biomarkers from organoid studies could transform the clinical management of patients at risk for TOC.

The collaboration between pathologists and translational researchers in this study is noteworthy, illustrating the importance of interdisciplinary approaches in modern biomedical research. Pathologists provide critical insight into the histological features of tumors, while translational researchers are equipped to explore therapeutic applications. This synergy is necessary for advancing our understanding of complex diseases, as each discipline brings unique expertise and perspectives to the table.

As the research led by Alves-Vale et al. progresses, it is clear that patient-derived organoids will play a crucial role in future therapeutic developments for tubo-ovarian carcinoma. The intricacies involved in the biology of this cancer call for novel methodologies and persistent inquiry, and organoids stand as a testament to innovative thinking in oncology research. The ongoing exploration into how these systems can enhance drug discovery, predict clinical outcomes, and personalize treatment regimens is paving the way for a new era of cancer therapy.

Ultimately, the potential to alter treatment landscapes through organoid technology cannot be understated. By fundamentally shifting how researchers investigate drugs and their effects on cancer, it brings hope for better therapeutic strategies against a disease that has remained stubbornly difficult to treat. With ongoing investments in this area, the promise of improved outcomes for patients with tubo-ovarian carcinoma becomes increasingly attainable. The integration of patient-derived organoids into research practices marks an important step towards creating a future where cancer treatment is not only more effective but more personalized to the needs of each individual patient.

As we stand on the cusp of further breakthroughs in understanding and treating tubo-ovarian carcinoma, all eyes will be on the application and evolution of these organoid models. Continuing to unravel the complexities of this disease through innovative research practices will undoubtedly lead to significant advancements in women’s health care and cancer therapy.

Subject of Research: Tubo-ovarian carcinoma and patient-derived organoids as a modeling tool.

Article Title: Patient-derived organoids as a model to study tubo-ovarian carcinoma: a pathologist’s perspective.

Article References:

Alves-Vale, C., Galvão, B., Silvestre, A.R. et al. Patient-derived organoids as a model to study tubo-ovarian carcinoma: a pathologist’s perspective.
J Ovarian Res 18, 191 (2025). https://doi.org/10.1186/s13048-025-01766-4

Image Credits: AI Generated

DOI: 10.1186/s13048-025-01766-4

Keywords: Tubo-ovarian carcinoma, patient-derived organoids, cancer research, personalized medicine, tumor microenvironment, drug screening, biomarkers.

BACDAC is not simply another addition to the genomic analysis toolkit; it represents a breakthrough in detecting the ploidy state of tumors by leveraging whole-genome DNA sequencing, even when confronted with low-purity or low-coverage samples—a frequent stumbling block in clinical genomics. Ploidy, the number of complete chromosome sets within a cell, is a fundamental biological parameter that cancer cells dramatically distort. While healthy human cells maintain a diploid state with two chromosome sets, malignant cells often display gains or losses in entire chromosome sets—a hallmark of genomic chaos that propels unchecked growth and therapeutic resistance.

The technical prowess of BACDAC lies in its ability to map allelic copy number variations across the genome through sophisticated computational algorithms that handle sparse data without sacrificing accuracy. This feature is particularly vital as it allows the tool to work effectively even in challenging scenarios where standard next-generation sequencing (NGS) might falter due to sample degradation or low tumor content. By quantifying these alterations, BACDAC offers a window into one of the most aggressive forms of chromosomal instability: whole-genome doubling, where the tumor’s entire DNA content is duplicated, essentially doubling its genomic material.

This phenomenon of whole-genome doubling has been closely linked with aggressive tumor phenotypes and poor clinical outcomes since it enhances the tumor’s ability to adapt and survive therapeutic assaults. Prior to BACDAC, detecting such large-scale genomic events required high-depth sequencing and often fresh, high-quality specimens, limiting practical clinical application. The new method’s scalability and robustness promise to overcome these limitations, enabling broader incorporation into both research and clinical diagnostics.

Beyond raw data, BACDAC introduces an innovative visualization technique known as the Constellation Plot. This bespoke graphical representation distills complex genomic data into an accessible, intuitive map that reveals the chromosomal stability or turbulence within a tumor. For clinicians and pathologists who wrestle daily with interpreting genomic information, the Constellation Plot could transform overwhelming data into actionable insights, streamlining decision-making processes crucial for personalized cancer therapy.

Developed through rigorous research involving the genomic analysis of over 650 tumor samples across 12 distinct cancer types, BACDAC’s validation process underscores its broad applicability and robustness. This comprehensive dataset enabled the researchers to benchmark the tool’s performance in detecting ploidy variations and structural genome rearrangements across diverse malignancies. The outcomes testify to BACDAC’s potential to serve as a universal instrument in cancer genomics, adaptable to a spectrum of tumor biology and clinical contexts.

The development of this tool is grounded in decades of foundational research on genomic instability, an area that has intrigued geneticists and oncologists alike due to its complex relationship with cancer progression. Yet, transforming theoretical insights into a practical, scalable technology represents a major leap. According to Dr. George Vasmatzis, co-director of Mayo Clinic’s Biomarker Discovery Program and lead author of the BACDAC study, this advancement marks a pivotal moment in applying deep biological knowledge to enhance genomic diagnostics at scale, propelling precision oncology closer to reality.

Looking forward, the Mayo Clinic team intends to further refine BACDAC and transition it from a research innovation into a clinically deployable diagnostic tool. This next phase involves extensive clinical validation, regulatory approval pathways, and potentially integration with existing sequencing platforms. The goal is clear: to empower oncologists with precise, reliable genomic information that can guide individualized treatment strategies, particularly for cancers exhibiting complex ploidy alterations that currently obscure prognosis and treatment planning.

The ramifications of translating BACDAC into clinical practice could be profound. By enabling detection of genomic instability events such as whole-genome doubling with minimal sample requirements, the tool could expand access to critical diagnostic insights for patients where tissue scarcity or quality has previously limited evaluation. This is especially pertinent as oncology increasingly shifts towards precision medicine paradigms, where understanding each tumor’s unique genomic landscape dictates therapeutic choices and clinical trial eligibility.

Moreover, BACDAC’s capacity to work with low-pass whole genome sequencing data—sequencing carried out at lower coverage to reduce costs and sample input—positions it as a cost-effective and accessible option for widespread deployment. This balance of sensitivity, accuracy, and efficiency could democratize access to comprehensive genomic profiling, narrowing the gap between cutting-edge research and everyday cancer care in diverse clinical settings.

The researchers acknowledge that while BACDAC addresses critical gaps in ploidy and structural variant detection, ongoing efforts will seek to integrate additional layers of genomic and epigenomic information to capture the multidimensional nature of tumor biology. Such integrations will further enhance the predictive power of genomic diagnostics, offering more nuanced insights into tumor evolution, resistance mechanisms, and therapeutic vulnerabilities.

In summary, the advent of BACDAC heralds a transformative step in cancer genomics—a tool capable of revealing the hidden layers of genomic instability that drive malignancy and thwart current diagnostic methods. By providing precise, scalable, and accessible detection of tumor ploidy changes and structural alterations, it opens new avenues for research and clinical management, fueling optimism that the genomic secrets of cancer will soon be more fully disclosed and leveraged to improve patient outcomes.

Subject of Research: Tumor ploidy determination and genomic instability detection using low-pass whole genome sequencing

Article Title: Tumor ploidy determination in low-pass whole genome sequencing and allelic copy number visualization using the Constellation Plot

News Publication Date: 20-Jun-2025

Web References:

• Mayo Clinic: https://www.mayoclinic.org/
• Study Publication (Genome Biology): https://genomebiology.biomedcentral.com/articles/10.1186/s13059-025-03599-2

References:
Vasmatzis G., et al. Tumor ploidy determination in low-pass whole genome sequencing and allelic copy number visualization using the Constellation Plot. Genome Biology. 2025.

Keywords: Cancer research, Cancer genomics, Cancer genome sequencing

Recent research has illuminated the critical role of ecDNA in tumor progression. Studies have documented its contribution to genetic heterogeneity within tumors, making the cancer cells more adaptable and difficult to eradicate. Moreover, the dynamics of ecDNA have profound implications for patient prognosis, as an active presence of ecDNA often correlates with poor outcomes. Despite these insights, the mechanisms by which ecDNA is replicated and maintained have remained elusive. The complexity underlying these biological processes has presented significant challenges for researchers seeking to delineate the functional roles of ecDNA in cancers.

In an important breakthrough, a team of researchers led by Prof. GAN Haiyun from the Shenzhen Institutes of Advanced Technology has made strides in unraveling the intricate relationship between ecDNA maintenance and the DNA damage response (DDR). Their findings, published in the prestigious journal Cell, enrich our understanding of the molecular interplay governing ecDNA biology. The research delineates a reciprocal regulatory relationship between ecDNA dynamics and DDR—an essential pathway that cells activate upon encountering DNA damage.

A significant impediment in ecDNA research has been the lack of reliable and well-controlled cellular models. To address this gap, Prof. GAN’s team employed CRISPR technology to generate two ecDNA-positive cell models. By creating matched pairs of cell lines, they have established a powerful platform for rigorous comparative studies. These engineered models allowed the researchers to generate compelling evidence supporting the notion that ecDNA is not merely a passive participant but actively undergoes replication and stabilization in tumor cells.

Through meticulous experimentation, the team demonstrated that ecDNA replication is not only a distinct process but is also tightly coupled with the activation of the ATM-mediated DDR pathway. In ecDNA-positive cells, enhanced activity of both replication and transcription was observed, highlighting the intricate dynamics of these processes. The researchers pinpointed that the collision of replication machinery or transcription complexes with topoisomerase-DNA complexes could result in the formation of abortive topoisomerase complexes, leading to double-strand breaks. This multifaceted interplay underscores the role of ecDNA in tumor biology and brings to light the risks that heightened replication activity poses to genomic integrity.

Furthermore, the team shed light on the mechanisms responsible for maintaining ecDNA. They uncovered that the alternative non-homologous end joining (alt-NHEJ) pathway is critical for repairing DNA damage associated with ecDNA. The experiments demonstrated that inhibiting essential components of the alt-NHEJ machinery, such as LIG3, resulted in significant disruptions to ecDNA circularization and led to reduced levels of ecDNA in tumor cells. These findings indicate that the maintenance of ecDNA is not merely a passive occurrence but is an actively regulated process that relies heavily on specific DNA repair pathways.

The research also delves into the translational aspects of these discoveries. The findings suggest that targeting the DDR and alt-NHEJ pathways may establish novel treatment strategies for cancers driven by ecDNA. Specifically, the study revealed that inhibiting DDR components selectively compromised the viability of ecDNA-positive cells, which underscores the potential for exploiting these pathways in therapeutic contexts. The implications are profound, as targeting these interactions could provide a dual benefit, undermining tumor survival while preserving normal cellular function.

Prof. GAN emphasized the significance of their findings, stating that their work enhances the understanding of how DDR plays a pivotal role in the dynamics of ecDNA and its evolutionary trajectory in tumors. While these insights are promising, the researchers acknowledge that further investigations are necessary to fully elucidate ecDNA’s impact on tumor heterogeneity, progression, and the mechanisms underlying drug resistance. The potential for therapeutic intervention lies in harnessing these mechanisms, presenting an exciting frontier for oncological research.

The research led by Prof. GAN marks a significant advancement in the understanding of ecDNA and its interplay with DNA damage responses. The insights gained from this study not only advance the field of cancer biology but also pave the way for innovative therapeutic strategies that could improve patient outcomes. Looking ahead, continued exploration of ecDNA dynamics and the associated molecular mechanisms will be crucial for developing effective interventions against tumors characterized by ecDNA-driven adaptations.

As we move forward, the potential for new diagnostics and therapeutic strategies derived from the understanding of ecDNA’s role in cancer progression appears promising. The intricate relationships defined by the research team provide fertile ground for future investigations. Indeed, targeting the pathways responsible for the maintenance and repair of ecDNA could yield transformative approaches in the battle against cancer, offering hope for more effective treatments tailored to individual patients’ tumor biology.

In conclusion, this groundbreaking research illuminates the complexities surrounding ecDNA, particularly its replication and the associated DNA damage response mechanisms that are crucial for tumor growth. By uncovering the relationship between these processes, the study lays the groundwork for future explorations aimed at addressing one of the most pressing challenges in oncology: overcoming the adaptability and resilience of cancer cells driven by extrachromosomal DNA.

Subject of Research: The Role of Extrachromosomal DNA in Tumor Biology and Its Interaction with DNA Damage Response Mechanisms
Article Title: Extrachromosomal DNA replication and maintenance couple with DNA damage pathway in tumors
News Publication Date: 28-Apr-2025
Web References: Cell Journal Article
References: Not Applicable
Image Credits: Not Applicable

Keywords

Pancreatic cancer notoriously presents a dismal prognosis, primarily because it is often diagnosed at an advanced stage when the disease has already metastasized, leaving patients with limited therapeutic options. Approximately 90% of pancreatic cancers are instigated by mutations in the KRAS gene, which stands as the most prevalent oncogenic mutation across various cancer types. Historically deemed "undruggable," the KRAS mutations have stymied researchers’ efforts for effective interventions. The recent approval of the first KRAS inhibitor in 2021 for treating non-small cell lung cancer highlighted some progress; however, emerging data indicated that KRAS-mutant cancers may rapidly adapt, developing resistance to therapies targeting specific mutants.

The lead author, Dr. Ben Stanger, MD, PhD, who is both the Hanna Wise Professor in Cancer Research and the director of the Penn Pancreatic Cancer Research Center, expressed enthusiasm for the research findings. "While the first wave of KRAS inhibitors have had limited impact in cancer care, this study reveals that newer RAS inhibition tools may possess immune stimulatory properties, making them ideal candidates for combination therapies with immunotherapy," he stated. This dual approach is expected to prolong therapeutic efficacy and improve overall patient outcomes.

In previous investigations, Dr. Stanger, alongside his colleague Dr. Robert Vonderheide, MD, DPhil, discovered that a small molecule compound selectively targeting KRAS G12D, a mutation prevalent in pancreatic cancer, could stimulate the immune system effectively while reducing tumor size in mouse models. This discovery laid the groundwork for exploring more advanced inhibitors that could enhance these effects when paired with immunotherapy.

The current research utilizes an innovative class of RAS(ON) multi-selective inhibitors, namely daraxonrasib (RMC-6236) and RMC-7977, both of which were developed by the biotechnology firm Revolution Medicines. These compounds employ an unconventional mechanism that permits them to target multiple active forms of RAS mutations simultaneously, offering potential flexibility in treatment responses should the cancer evolve and develop additional mutations.

The preclinical models used in this study were particularly noteworthy as they employed a Penn-developed immunocompetent model, recognized globally for assessing therapeutic outcomes in pancreatic ductal adenocarcinoma. This model enables tumors to evolve naturally after being implanted, allowing researchers to accurately evaluate the drug’s influence on the tumor microenvironment. The findings revealed that the multi-selective RAS inhibition not only effectively reduced tumor sizes but also transformed the tumor microenvironment by enhancing the infiltration of immune cells, particularly T cells, creating a setting that is more amenable to immunotherapy.

When daraxonrasib was combined with immunotherapy, the results were striking. In all tested mouse models, researchers observed noticeable tumor shrinkage, with half of the subjects experiencing a complete response, indicating that the tumors were effectively eradicated. This level of efficacy is particularly encouraging for a cancer type that has been notoriously stubborn in response to conventional therapies.

As clinical trials begin for daraxonrasib, the research team’s results support the hopeful emergence of combination therapies that leverage both targeted and immunotherapeutic strategies. A prominent clinical trial is already underway, targeting patients with specific gastrointestinal solid tumors to investigate the efficacy of RAS(ON) inhibitors in conjunction with other anticancer agents. These trials are rolled out in various locations across the United States, with specific sites at Penn Medicine.

The implications of this research extend far beyond the laboratory. Elucidating how RAS inhibition can synergize with immunotherapy represents a transformative step toward developing a comprehensive treatment paradigm for pancreatic cancer. Dr. Vonderheide expressed optimism, stating, "We are hopeful that we are beginning to crack the code on immunotherapy and RAS therapy for pancreatic cancer." Given the historical stagnation in therapeutic advancements within this domain, the manuscript can spark renewed interest and investment in pancreatic cancer research.

The support for this research underscores a concerted effort involving multiple stakeholders, including Revolution Medicines and significant funding from the National Institutes of Health and the Department of Defense. Such collaborations are critical in accelerating breakthroughs and translating preclinical findings into viable clinical options for patients in dire need.

As the scientific community eagerly anticipates the results of forthcoming clinical trials, the prospect of transforming pancreatic cancer treatment is becoming more tangible. The combination of novel multi-selective inhibitors with innovative immunotherapies could indeed herald a new era in cancer treatment that offers real hope to patients facing what once seemed like an insurmountable challenge.

In conclusion, the investigation conducted by the researchers at the University of Pennsylvania provides compelling evidence that selecting for multiple KRAS mutations in conjunction with immunotherapy represents a promising frontier in managing pancreatic cancer. This new collaborative approach could accelerate the development of effective therapies that address the complexities of cancer biology, with the ultimate goal of improving patient survival and quality of life.

Subject of Research: Pancreatic cancer treatment strategies leveraging multi-selective RAS inhibitors and immunotherapy.
Article Title: T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDAC.
News Publication Date: March 7, 2025.
Web References: Cancer Discovery DOI
References: Not applicable.
Image Credits: Not applicable.

Keywords: Pancreatic cancer, KRAS mutation, immunotherapy, targeted therapy, RAS inhibitors, cancer treatment, preclinical models, tumor microenvironment, combination therapy, clinical trials.